Skip to main content

Table 1 Demographics and baseline characteristics for all participants

From: Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial

 

Overall (N = 36)

Age (yr)

Mean (SD)

34.8 (14.9)

Median (min:max)

29.9 (18.6:65.9)

Sex, n (%)

Female

22 (61)

Male

14 (39)

Race, n (%)

Asian

2 (6)

White

32 (89)

Other

2 (6)

Ethnicity, n (%)

Hispanic or Latino

11 (31)

Not Hispanic or Latino

24 (67)

Not Reported

1 (3)

Age at ASMD diagnosis (yr)

Mean (SD)

18.0 (18.4)

Median (min:max)

6.4 (1:58)

Years since ASMD diagnosis

Mean (SD)

16.8 (13.5)

Median (min:max)

16.3 (0:51)

ASM activity (peripheral leukocytes), nmol/h/mg

Mean (SD)

0.119 (0.079)

Median (min:max)

0.10 (0:0.30)

SMPD1 genotype, n (%)

Homozygous forArg610del

5 (13.9)

Heterozygous for Arg610del

10 (27.8)

Other variants

21 (58.3)